



Vaccine Update #470 – Shelf-life Extension –ABRYSVO

Shelf-life Extension – ABRYSVO (RSV vaccine)

Pfizer Australia Pty Ltd advises that, following the Therapeutic Goods Administration (TGA) approval, the shelf life of the below listed batches of ABRYSVO is extended an additional 48 months. The requirement to store ABRYSVO in a refrigerator (2°C - 8°C) prior to reconstitution remains unchanged. For full storage requirements before and after reconstitution, please refer to the ABRYSVO® Product Information available on the TGA website. Please refer to the table below for the updated expiry dates.

Batch number	Updated expiry date
MA7999	31.07.2027
LR6778	30.05.2028
LX9458	31.05.2028
MR6675	31.07.2028

If you are currently in possession of ABRYSVO® stock with batch numbers different to those listed above, the expiry date remains unchanged. Please continue to use the printed expiry date on the packaging.

If you have stock with the affected batches, you will be mailed stickers with your vaccine delivery starting in two weeks. In the meantime, please use the information above, and mark your vaccines accordingly. Please follow the below instructions to add the expiry date extension sticker to your ABRYSVO® pack.



EXP: _____ / _____
Month Year

For more information on expiry extension
for ABRYSSVO® scan the QR code

What you need to do:

1. Check your stock batch number - locate affected ABRYSSVO stock
2. Add the expiry date extension sticker to your ABRYSSVO pack on the panel highlighted below.
2. Make sure the Lot number is not covered.

This document can be made available in alternative formats on request for a person with disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.



PLEASE REVIEW THE AUSTRALIAN PRODUCT INFORMATION BEFORE PRESCRIBING OR DISPENSING.

The ABRYSSVO Product Information and Consumer Medicine Information can be found at <https://www.ebs.tga.gov.au/> or by scanning the QR Code below.

This document can be made available in alternative formats on request for a person with disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

health.wa.gov.au



Please refer to the RSV chapter in the [Australian Immunisation Handbook](#) for detailed advice, vaccine dosage, and contraindications.

Adverse event and cold chain breach reporting

[Reporting of adverse events following immunisation \(AEFI\)](#) to the Western Australian Vaccine Safety Surveillance (WAVSS) system is a condition of Structured Administrations and Supply Arrangements (SASAs) that provide the authority for immunisation providers to safely administer vaccinations in WA.

ABRYSVO is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Please report any suspected adverse events to WAVSS at <https://www.safevac.org.au/>

To receive government-funded vaccines and immunisations, providers must follow the WA [cold chain protocol](#). Providers must advise their [WA Health Public Health Unit](#) when a cold chain breach occurs or to seek thermal stability advice for other incidents where government-funded vaccines and immunisations are involved. To report any cold chain breach or wastage, please refer to [WA Department of Health Cold Chain Management webpage](#).

Medical Enquiries

Should you have any questions regarding this matter, please contact Pfizer Medical Information on 1800 675 229 or via www.pfizermedicalinformation.com.au

This document can be made available in alternative formats on request for a person with disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.